# Immunotherapy With Vacc-C5 With Adjuvant GM-CSF or Alhydrogel in HIV-1-infected Subjects on ART

> **NCT01627678** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bionor Immuno AS** · enrollment: 36 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** Vacc-C5/GM-CSF
- **DRUG:** Vacc-C5/Alhydrogel

## Key facts

- **NCT ID:** NCT01627678
- **Lead sponsor:** Bionor Immuno AS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2014-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01627678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01627678, "Immunotherapy With Vacc-C5 With Adjuvant GM-CSF or Alhydrogel in HIV-1-infected Subjects on ART". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01627678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*